1. Academic Validation
  2. Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse

Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse

  • Front Mol Neurosci. 2019 Jan 9:11:490. doi: 10.3389/fnmol.2018.00490.
Laura Orio 1 2 Francisco Alen 1 Francisco Javier Pavón 2 3 Antonia Serrano 2 3 Borja García-Bueno 4 5
Affiliations

Affiliations

  • 1 Department of Psychobiology and Methods in Behavioral Science, Faculty of Psychology, Complutense University of Madrid, Madrid, Spain.
  • 2 Red de Trastornos Adictivos (RTA), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • 3 Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga-Universidad de Málaga, Málaga, Spain.
  • 4 Department of Pharmacology and Toxicology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
  • 5 Centro de Investigación Biomédica en Red de Salud Mental, IMAS and IUING, Madrid, Spain.
Abstract

Neuroinflammation is a complex process involved in the physiopathology of many central nervous system diseases, including addiction. Alcohol abuse is characterized by induction of peripheral inflammation and neuroinflammation, which hallmark is the activation of innate immunity toll-like receptors 4 (TLR4). In the last years, lipid transmitters have generated attention as modulators of parts of the addictive process. Specifically, the bioactive lipid oleoylethanolamide (OEA), which is an endogenous acylethanolamide, has shown a beneficial profile for alcohol abuse. Preclinical studies have shown that OEA is a potent anti-inflammatory and antioxidant compound that exerts neuroprotective effects in alcohol abuse. Exogenous administration of OEA blocks the alcohol-induced TLR4-mediated pro-inflammatory cascade, reducing the release of proinflammatory cytokines and chemokines, oxidative and nitrosative stress, and ultimately, preventing the neural damage in frontal cortex of rodents. The mechanisms of action of OEA are discussed in this review, including a protective action in the intestinal barrier. Additionally, OEA blocks cue-induced reinstatement of alcohol-seeking behavior and reduces the severity of withdrawal symptoms in Animals, together with the modulation of alcohol-induced depression-like behavior and Other negative motivational states associated with the abstinence, such as the anhedonia. Finally, exposure to alcohol induces OEA release in blood and brain of rodents. Clinical evidences will be highlighted, including the OEA release and the correlation of plasma OEA levels with TLR4-dependent peripheral inflammatory markers in alcohol abusers. In base of these evidences we hypothesize that the endogenous release of OEA could be a homeostatic signal to counteract the toxic action of alcohol and we propose the exploration of OEA-based pharmacotherapies to treat alcohol-use disorders.

Keywords

OEA oleoylethanolamide; acylethanolamides; alcohol; drugs of abuse; inflammation; lipids; neuroinflammation; neuroprotection.

Figures
Products